CONTENTS

EDITORIALS

* jgo.2019.30.e119
  Therapeutic vaccination using HPV 16 E7 to eradicate CIN3
  Tewari KS.

* jgo.2019.30.e117
  Fertility sparing treatment for early stage endometrial cancer: current situation and new strategy
  Ushijima K.

* jgo.2019.30.e116
  Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
  Zang R, Zhu J.

MEETING REPORTS

* jgo.2019.30.e114
  The 61st Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO)
  Yoshihara K, Sekine M, Nishino K, Enomoto T.

* jgo.2019.30.e118
  The Annual Meeting of the Thai Gynecologic Cancer Society 2019: Meeting report
  Charoenkwan K, Srisomboon J.

SOCIETY NEWS

* jgo.2019.30.e115
  ASGO, KSGO, and JSGO announce collaboration

* jgo.2019.30.e110
  Reviewer recognition in 2019
  Journal of Gynecologic Oncology (JGO) Editorial Office.

ORIGINAL ARTICLES

CERVIX

* jgo.2019.30.e88
  A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3
  Park YC, Ouh YT, Sung MH, Park HG, Kim TJ, Cho CH, Park JS, Lee JK.
**UTERINE CORPUS**

*jgo.2019.30.e89*
Prognostic value of metabolic tumor volume and total lesion glycolysis from \(^{18}\text{F}-\text{FDG PET/CT}\) in lymph node metastases and risk stratification of endometrial carcinoma
Liu DD, Li J, Li X, Xie L, Qin L, Peng F, Cheng MH.

*jgo.2019.30.e90*
Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients

*jgo.2019.30.e103*
Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan

**OVARY**

*jgo.2019.30.e85*
Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma

*jgo.2019.30.e83*
The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4
Han KH, Park NH, Kim JI, Kim S, Kim HS, Lee M, Song YS.

*jgo.2019.30.e93*
Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer
Chambers LM, Son J, Radeva M, DeBernardo R.

*jgo.2019.30.e95*
Accuracy of frozen section diagnosis and factors associated with final pathological diagnosis upgrade of mucinous ovarian tumors
Park JY, Lee SH, Kim KR, Kim YT, Nam JH.
**jgo.2019.30.e96**
Relationship between the precursors of high grade serous ovarian cancer and patient characteristics: decreased incidence of the p53 signature in pregnant women
Ida T, Fujiwara H, Kiriu T, Taniguchi Y, Kohyama A.

**jgo.2019.30.e99**
Concurrence of ovarian cancer and dermatomyositis: a propensity score analysis
Cheng H, Huo L, Wang D, Xiang Y.

**jgo.2019.30.e100**
The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients
So M, Miyamoto T, Murakami R, Abiko K, Hamanishi J, Baba T, Mandai M.

**jgo.2019.30.e102**
Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis
Yoshihara M, Kajiyama H, Tamauchi S, Suzuki S, Takahashi K, Matsui S, Kikkawa F.

**IMMUNOTHERAPY**

**jgo.2019.30.e94**
Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience
Indini A, Di Guardo L, Cimminiello C, Lorusso D, Raspagliesi F, Del Vecchio M.

**CLINICAL TRIAL PROTOCOL**

**jgo.2019.30.e112**
A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D

**CORRESPONDENCES**

**jgo.2019.30.e111**
Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
Batista TP, Kusamura S.
Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study
Machida H, Matsuo K, Enomoto T, Mikami M